FDA panel votes in favor of Quad for HIV

FDA's Antiviral Drugs Advisory Committee voted 13-1 that the benefit-risk profile of the fixed-dose Quad regimen from Gilead Sciences Inc. (NASDAQ:GILD) supports approval to treat HIV-1 infection in t...